Pharmacological blockade of 5HT2A suppresses tumor proliferation and extends survival in vivo, whereas psilocybin-induced activation of 5HT2A elicits sustained calcium transients and persistently enhances glioma growth. The gene discussed is HTR2A; the disease is central nervous system cancer.